Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Rating of "Buy" from Brokerages

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) has been given an average rating of "Buy" by the five brokerages that are presently covering the stock, Marketbeat Ratings reports. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $12.38.

A number of research analysts have weighed in on CRVS shares. HC Wainwright began coverage on shares of Corvus Pharmaceuticals in a research note on Thursday. They issued a "buy" rating and a $11.00 target price on the stock. Mizuho upgraded Corvus Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, October 22nd. StockNews.com downgraded Corvus Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Thursday, October 31st. Oppenheimer boosted their target price on Corvus Pharmaceuticals from $8.00 to $14.00 and gave the company an "outperform" rating in a research note on Wednesday, November 13th. Finally, LADENBURG THALM/SH SH increased their price target on Corvus Pharmaceuticals from $12.00 to $21.00 and gave the stock a "buy" rating in a research note on Monday, September 16th.

Institutional Investors Weigh In On Corvus Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Nwam LLC bought a new position in shares of Corvus Pharmaceuticals in the third quarter worth $53,000. XTX Topco Ltd bought a new position in Corvus Pharmaceuticals in the 3rd quarter worth about $74,000. Virtu Financial LLC bought a new position in Corvus Pharmaceuticals in the 3rd quarter worth about $83,000. Oppenheimer & Co. Inc. purchased a new stake in shares of Corvus Pharmaceuticals in the 3rd quarter valued at about $89,000. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of Corvus Pharmaceuticals during the 2nd quarter valued at about $44,000. 46.64% of the stock is currently owned by institutional investors.

Corvus Pharmaceuticals Price Performance

Shares of Corvus Pharmaceuticals stock traded up $0.08 during trading hours on Thursday, hitting $5.43. 909,045 shares of the company's stock traded hands, compared to its average volume of 490,841. The stock has a market capitalization of $348.92 million, a price-to-earnings ratio of -5.84 and a beta of 1.05. Corvus Pharmaceuticals has a 12-month low of $1.30 and a 12-month high of $10.00. The company has a fifty day simple moving average of $7.72 and a 200-day simple moving average of $5.26.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.